A Study of LY4337713 in Participants With FAP-Positive Solid Tumors (NCT07213791)
A Dose Escalation and Dose Optimization Phase 1a/1b Study to Evaluate Safety, Tolerability and Dosimetry of Radioligand Therapy With LY4337713 in Adults With FAP-Positive Solid Tumors (FiREBOLT)
🩺 Plain-English Summary (8th-Grade Level)
This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP). The purpose of this study is to evaluate safety, side effects, and efficacy of LY4337713. In addition, this study will evaluate how much LY4337713 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. For each participant, the study will last about 5 years.
Who can join: Review the eligibility criteria below.
Location: Hoag Memorial Hospital Presbyterian — Newport Beach, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (30 Sites)
Showing the first 25 of 30 sites.
- Hoag Memorial Hospital Presbyterian — Newport Beach, California
- Stanford University Medical Center — Stanford, California
- Biogenix Molecular, LLC — Miami, Florida
- Moffitt — Tampa, Florida
- Indiana University (IU) School of Medicine — Indianapolis, Indiana
- United Theranostics — Glen Burnie, Maryland
- Massachusetts General Hospital — Boston, Massachusetts
- Beth Israel Deaconess Medical Center — Boston, Massachusetts
- Barbara Ann Karmanos Cancer Institute — Detroit, Michigan
- BAMF Health Inc. — Grand Rapids, Michigan
- Mayo Clinic - Rochester — Rochester, Minnesota
- Washington University School of Medicine in St. Louis — St Louis, Missouri
- New York University (NYU) Clinical Cancer Center — New York, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center — New York, New York
- Duke University Medical Center — Durham, North Carolina
- University of Pennsylvania — Philadelphia, Pennsylvania
- Fox Chase Cancer Center — Philadelphia, Pennsylvania
- Texas Oncology - DFW (Sammons CC) — Dallas, Texas
- Baylor College of Medicine — Houston, Texas
- University of Wisconsin - Carbone Cancer Center — Madison, Wisconsin
- Fudan University Zhongshan Hospital — Shanghai,
- Universitaetsklinikum Essen — Essen,
- National Cancer Center Hospital East — Chiba,
- Kyoto University Hospital — Kyoto,
- Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis (NKI-AVL) — Amsterdam,
📞 Contact the Study Coordinator
Phone: (317) 615-4559
Email: LillyTrials@Lilly.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Ovarian Neoplasms
- A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy — Tempe, Arizona
- A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer — Anchorage, Alaska
- BMX-001 + Paclitaxel in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial Cancer — Durham, North Carolina
- Ovarian Cancer Liquid Biopsy for Early Assessment & Detection in Individuals With BRCA1/2 Pathogenic Variants — New York, New York
- Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer — Little Rock, Arkansas
- A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01) — Randwick, New South Wales
Explore by condition: All Ovarian Neoplasms clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.